Blood Reviews
Volume 20, Issue 6 , Pages 289-297 , November 2006

Haemostatic problems in acute promyelocytic leukaemia

References 

  1. Tornebohm E, Blomback M, Lockner D, Egberg N, Paul C. Bleeding complications and coagulopathy in acute leukaemia. Leuk Res. 1992;16:1041–1048
  2. Lisiewicz J. Disseminated intravascular coagulation in acute leukaemia. Seminars in Thrombos and Haemostas. 1988;14:339–350
  3. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukaemia: A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75:2112–2117
  4. Warrell RP, de The H, Wang Z-Y, Degos L. Acute promyelocytic leukaemia. N Engl J Med. 1993;329:177–189
  5. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Practice & Research Clin Haematol. 2003;16:463–482
  6. Tallman MS, Brenner B, de la Serna J. Meeting report. Leuk Res. 2005;29:347–351
  7. Wilde JT, Davies JM. Haemostatic Problems in Acute Leukaemia. Blood Reviews. 1990;4:245–251
  8. Myers TJ, Rickles FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukaemia: relationship of activation of blood coagulation to disease activity. Blood. 1981;57:518–525
  9. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukaemia. Blood. 1984;64:791–796
  10. Bosclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E. Br J Haematol. 1990;74:471–479
  11. Tallman MS, Hakimian D, KWaan HC, Rickles FR. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukaemia. Leuk Lymph. 1993;11:27–36
  12. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid. Blood. 1995;86:1072–1081
  13. Dombret H, Scrobohaci ML, Ghorra P, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia. 1993;7:2–9
  14. Dombret H, Scrobohaci ML, Daniel MT, et al. In vivo thrombin and plasmin activites in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia. 1995;9:19–24
  15. Polliak A. Acute promyelocytic leukemia with disseminated intravascular coagulation. Am J Clin Path. 1971;56:155–161
  16. Gralnick HR, Bagley J, Abrell E. Heparin treatment for the haemorrhagic diathesis of acute promyelocytic leukemia. Am J Med. 1972;52:167–174
  17. Gouault-Heilman M, Chardon E, Sultan E, Josso F. The procoagulant factor of leukemic promyelocytes: Demonstration of immunologic cross-reactivity with human brain tissue factor. Br J Haematol. 1975;30:151–158
  18. Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer. 1987;59:748–754
  19. Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Throm Res. 1989;56:425–430
  20. Tanaka M, Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemia cells. Leuk Res. 1997;17:103–111
  21. Pedrera CL, Jardi M, Malogon M, et al. TF and u-PAR and bleeding complications in leukemic patients. Thrombos Haemostas. 1997;77:62–70
  22. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood. 1988;71:870–875
  23. Donati MB, Falanga A, Consonni R, et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost. 1990;64:11–16
  24. Vellenga E, Mulder NH. Normal levels of antithrombin III in acute leukaemia complicated by coagulopathy. Acta Haematologica. 1980;63:336–338
  25. Sandler RM, Liebman HA, Patch MJ, Teitelbaum A, Levine AM, Feinstein DI. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukaemia and disseminated intravascular coagulation treated with heparin. Cancer. 1982;50:2106–2110
  26. Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol. 1988;70:43–48
  27. Speiser W, Pabinger-Fasching I, Kyrle PA, et al. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukaemia: Activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut. 1990;61:298–302
  28. Plow EF, Edgington TS. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest. 1975;56:30–38
  29. Nossel HL, Hurlet-Jensen A, Lui CY, Koehn JA, Canfield RE. Fibrinopeptide release from fibrinogen. Ann N Y Acad Sci. 1983;408:269–277
  30. Bennett M, Parker AC, Ludlam CA. Platelet and fibrinogen survival in acute promyelocytic leukaemia. BMJ. 1976;(2):565
  31. Booth NA, Bennett B. Plasmin-alpha2-antiplasmin complexes in bleeding disorders characterised by primary or secondary fibrinolysis. Br J Haematol. 1984;56:545–556
  32. Imaoka S, Ueda T, Shibata H, et al. Fibrinolysis in patients with acute promyelocytic leucemia and disseminated intravascular coagulation during heparin therapy. Cancer. 1986;58:1736–1738
  33. Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha2-plasmin inhibitor deficiency. Ann Intern Med. 1986;105:873–877
  34. Reddy VB, Kowal-Vern A, Hoppensteadt DA, et al. Global and hemostatic markers in acute leukemia. Am J Clin Pathol. 1990;94:397–403
  35. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood. 1991;77:1949–1957
  36. Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic lekuemia. Br J Haematol. 1973;24:89–99
  37. Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71:511–517
  38. Tapiovaara H, Alitalo R, Stephens R, Myohanen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukaemia patients. Blood. 1993;82:914–919
  39. Stephens R, Alitalo R, Tapiovaara H, Vaheri A, et al. Production of an active urokinase by leukaemia cells. A novel distinction from cell lines of solid tumors. Leuk Res. 1988;12:419–422
  40. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukaemia. N Engl J Med. 1999;340:994–1004
  41. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269:21191–21197
  42. Hajjar KA, Menell JS. Annexin II: a novel mediator of cell surface plasmin generation. Ann N Y Acad Sci. 1997;811:337–349
  43. Cesarman GM, Guevara CA, Hajjar KA. An endotelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA dependent plasminogen activation. J Biol Chem. 1994;269:21198–21203
  44. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloid cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987;70:1218–1221
  45. Cozzolino F, Torcia M, Miliani A, et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med. 1988;84:240–250
  46. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium.: Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA. 1986;83:4533–4537
  47. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989;73:159–165
  48. Nachman RL, Hajjar KA, Siverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med. 1986;163:1595–1600
  49. Egbring R, Schmidt W, Fuchs G, Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood. 1977;49:219–231
  50. Schmidt W, Egbring R, Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isoltaed clotting factors. Thromb Res. 1975;6:315–326
  51. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of a2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem. 1982;257:9849–9854
  52. Sterrenberg L, van Liempt GJ, Nieuwenhuizen W, Hermans J. Anticoagulant properties of purified X-like fragments of human fibrinogen produced by degradation with leukocyte elastase. Thromb Haemost. 1984;51:398–402
  53. Oudijk E-JD, Nieuwenhuizen HK, Bos R, Fijnheer R. Elastase mediated fibrinolysis in acute promyelocytic leukaemia. Thromb Haemost. 2000;83:906–908
  54. Federici AB, Berkowitz SD, Lattuada A, Mannucci PM. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood. 1993;81:720–725
  55. Federici AB, Falanga A, Lattuada A, Di Rocco N, Barbui T, Mannucci PMM. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-trans-retinoic acid. Br J Haematol. 1996;92:733–739
  56. Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia. Best Practice & Research Clin Haematol. 2001;14:153–174
  57. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298–4302
  58. Arlin Z, Kempin S, Mertelsmann R. Primary therapy of acute promyelocytic leukemia: role of amsacrine and daunorubicin based therapy. Blood. 1984;63:211–212
  59. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukaemia. Blood. 1995;85:2643–2653
  60. Cordonnier C, Vernant JP, Brun B. Acute promyelocytic leukaemia in 57 previously untreated patients. Cancer. 1985;55:18–25
  61. Kantarjian H, Keating M, Walters R. Acute promyelocytic leukaemia. MD Anderson Hospital Experience. Am J Med. 1986;80:789–797
  62. British Committee for Standards in Haematology, Blood Transfusion Task Force . Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10–23
  63. British Committee for Standards in Haematology, Blood Transfusion Task Force . Guidelines for the use of fresh-frozenplasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28
  64. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–592
  65. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: From genetics to treatment. Blood. 1994;83:10–25
  66. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukaemia. Blood. 1990;76:1704–1709
  67. Kawai Y, Watanabe K, Kizaki M, et al. Rapid improvement of coagulopathy by all-trans-retinoic acid in acute promyelocytic leukemia. Am J Hematol. 1994;46:184–188
  68. Fenaux P, Le Deley MC, Chastang C, et al. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomised trial. Blood. 1993;82:3241–3249
  69. Keane TJ, Gorman AM, O’Connell LG, Fenelly JJ. Epsilon-amino-caproic acid in the management of acute promyelocytic leukaemia. Acta Haematol. 1976;56:202–204
  70. Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic aicd in the treatment of patients with acute promyelocytic leukaemia and acquired alpha2-plasmin inhibitor deficiency. Ann Int Med. 1986;105:873–877
  71. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2:122–124
  72. Sugawara T, Okuda M, Yamaguchi Y, Endo K, Yoshinaga K. Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia. Acta Haematol. 1992;87:109
  73. Runde V, Aul C, Sudhoff T, Heyll A, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia. Blood. 1992;79:534–535
  74. Forjaz De Lacenda J, Alves Do Carmo J, Lurdes Guerna M, Geraldes J, Forjaz De Lacerda JM. Multiple thrombosis in acute promyelocytic leukaemia after tretoin. Lancet. 1993;342:114
  75. Hashimoto S, Koike T, Tatewaki W. Fatal thromboembolism in acute promyelocytoc leukaemia during all-trans retinoic acid therapy combined with ant-fibrinoytic therapy for prophylaxis of hemorrhage. Leukemia. 1994;8:1113–1115
  76. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukaemia treated with and without all-trans retinoic acid. Leuk Lymphoma. 1996;20:435–439
  77. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans-retinoic acid upregulates thrombomodulin and downregulates tissue factor expression in acute promyelocytic leukaemia cells. Distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood. 1994;84:3001–3009
  78. De Stefano V, Teofili L, Sica S, et al. Effect of all-trans-retinoic on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood. 1995;86:3535–3541
  79. Saito T, Koyama T, Nagata K, Kamiyama R, Hirosawa S. Anticoagulant effects of retionoic acids on leukaemia cells. Blood. 1996;87:657–665
  80. Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid. Leukemia. 1994;8:156–159
  81. Zhu J, Guo WM, Yao YY, et al. Tissue factors on acute promyelocytic leukaemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999;13:1062–1070
  82. Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia cells. Blood. 1998;92:143–151
  83. Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood. 1994;83:1883–1891
  84. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998;91:3093–3102
  85. Dubois C, Schlageter MH, de Gentile , et al. Modulation of IL-8, IL-1β and G-CSF by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia. 1994;8:1750–1757
  86. Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induce by a human promyelocytic leukemia-derived cell line (NB4). Blood. 1996;87:613–617
  87. Ishii H, Horie S, Kizaki K, Kazama M. Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured endothelial cells exposed to tumor necrosis factor. Blood. 1992;80:2556–2562
  88. Horie S, Kizaki K, Ishii H, Kazama M. Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells: Differences between up-regulation of thrombomodulin by retinoic acid and cyclic AMP. Biochem J. 1992;281:149–154
  89. Kooistra T, Opdenberg JP, Toet K, Hendriks HFJ, van den Hoogen RM, Emeis JJ. Stimulation of tissue-type plasminogen activators synthesis by retionoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost. 1991;65:565–572
  90. Medh RD, Santell L, Levin EG. Stimulation of tissue plasminogen activator production by reinoic acid: Synergistic effect on protein kinase C-mediated activation. Blood. 1992;80:981–987

PII: S0268-960X(06)00029-4

doi: 10.1016/j.blre.2006.04.001

Blood Reviews
Volume 20, Issue 6 , Pages 289-297 , November 2006

Article Tools

* Image Usage & Resolution